Would you consider additional chemotherapy in this patient?
Patients with leiomyosarcoma are often treated with targeted therapies. One of the major therapies that we use is pazopanib. Pazopanib is a multi-targeted tyrosine kinase inhibitor (TKI) that targets KIT, VEGF receptors, and PDGF receptors. A newer agent called trabectedin targets the minor groove of DNA, and it's thought to interfere with the transcription of certain factors that interfere with the tumor cell phenotype.
CASE: Soft-Tissue Sarcoma (Part 1)
Rachel F is a 58-year-old school teacher from Roanoke, Virginia. Her medical history is notable for mild hypertension and total knee replacement in 2011
Follow-up CT scan in January 2014 showed progression at multiple sites; at the time of follow up, her ECOG performance status was 1, with renal and hepatic function within normal limits
In September of 2014 she returns for follow-up, unable to work with increasing fatigue and abdominal pain, and her CT scan was consistent with progressive disease
After 4 months of therapy, she presents with worsening abdominal pain and declining performance status
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More